Ytterbium-169 ion (169Yb)

Ytterbium-169 is a radioisotope of the lanthanide element ytterbium with a half-life of approximately 32 days [1]. It decays via electron capture to stable thulium-169, emitting a spectrum of gamma rays and low-energy Auger electrons [1]. In clinical medicine, Ytterbium-169 is not a biological target like a receptor or enzyme, but rather a therapeutic and diagnostic agent [2]. It is most commonly utilized in the form of Ytterbium-169 DTPA for radionuclide cisternography to evaluate cerebrospinal fluid flow and detect leaks [2]. Additionally, it has been investigated as a source for brachytherapy due to its favorable energy spectrum for treating localized malignancies [3]. The therapeutic effect is achieved through ionizing radiation, which induces lethal DNA damage in targeted cells [3]. Safety considerations include the risk of radiation exposure to healthy tissues and the potential for bone marrow suppression [1]. Sources: [1] PubChem (CID 104824); [2] StatPearls (Radionuclide Cisternography); [3] Medich et al. (2006), Journal of Contemporary Brachytherapy.

Other names

169YbYtterbium-169Yb-169Radioytterbium-169

Ytterbium-169 acts as a source of ionizing radiation; it decays by electron capture, emitting gamma rays and Auger electrons that cause localized ionization and double-strand DNA breaks, leading to cell death in targeted tissues [1, 3].